{"id":"bortezomib-rituximab-bendamustine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bortezomib targets the proteasome, disrupting cell growth and survival. Rituximab targets CD20 on B cells, leading to their depletion. Bendamustine is a chemotherapy agent that interferes with DNA replication and repair.","oneSentence":"Bortezomib-Rituximab-Bendamustine is a combination of a proteasome inhibitor, a monoclonal antibody, and a chemotherapy agent.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:38.367Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT01415752","phase":"PHASE2","title":"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2012-08-09","conditions":"Lymphoma, Mantle Cell Lymphoma","enrollment":373},{"nctId":"NCT01216683","phase":"PHASE2","title":"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-02-09","conditions":"Lymphoma","enrollment":289},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT02371148","phase":"PHASE2","title":"Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-06","conditions":"Waldenstrom's Macroglobulinemia","enrollment":38},{"nctId":"NCT00889798","phase":"","title":"Tumor Registry of Lymphatic Neoplasia","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2009-04","conditions":"Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)","enrollment":3795},{"nctId":"NCT01029730","phase":"PHASE2","title":"Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2010-03","conditions":"Lymphoma","enrollment":55},{"nctId":"NCT00740415","phase":"PHASE2","title":"Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2007-06","conditions":"Lymphoma","enrollment":39},{"nctId":"NCT01457144","phase":"PHASE2","title":"Study of Mantle Cell Lymphoma Treatment by RiBVD","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2011-10","conditions":"Mantle Cell Lymphoma","enrollment":76},{"nctId":"NCT00547534","phase":"PHASE2","title":"Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2007-10","conditions":"Non-Hodgkin's Lymphoma","enrollment":31},{"nctId":"NCT00636792","phase":"PHASE2","title":"A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2008-02","conditions":"Follicular Lymphoma","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BRB"],"phase":"phase_2","status":"active","brandName":"Bortezomib-Rituximab-Bendamustine","genericName":"Bortezomib-Rituximab-Bendamustine","companyName":"Fondazione Italiana Linfomi - ETS","companyId":"fondazione-italiana-linfomi-ets","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bortezomib, Rituximab, and Bendamustine are interventions studied in clinical trials for various conditions, including Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Indolent Non-Hodgkin's Lymphoma, and Chronic Lymphocytic Leukemia. Rituximab, a B-lymphocyte antigen CD20 binding agent, is an antibody that binds to CD20, a molecular target on B-lymphocytes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}